Targeted, Orally Delivered Therapies for Gastrointestinal Diseases
THE SCIENCE
Entero Therapeutics’ product portfolio is built around its three proprietary technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to break up gluten and reduce celiac disease symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist with gastrointestinal (GI) indications; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
LEARN MOREPIPELINE
Entero Therapeutics’ GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by autoimmune malfunction. Disease targets include patient populations with digestive disorders, such as celiac disease, gastroparesis, exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis, and inflammatory bowel diseases such as ulcerative colitis.
IN THE NEWS
|
Sep 10, 2024
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
|
|
Aug 23, 2024
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
|
|
Jul 31, 2024
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
|
